Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250–6. https://doi.org/10.1002/jmv.26232.

Article  CAS  PubMed  Google Scholar 

Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023;14:1125246. https://doi.org/10.3389/fimmu.2023.1125246.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305–15. https://doi.org/10.1056/NEJMoa2116846.

Article  CAS  PubMed  Google Scholar 

Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, et al. Real-world clinical outcomes of Bamlanivimab and Casirivimab-Imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. J Infect Dis. 2021;224:1278–86. https://doi.org/10.1093/infdis/jiab377.

Article  CAS  PubMed  Google Scholar 

Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50. https://doi.org/10.1056/NEJMoa2107934.

Article  CAS  PubMed  Google Scholar 

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397–408. https://doi.org/10.1056/NEJMoa2118542.

Article  CAS  PubMed  Google Scholar 

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436.

Article  CAS  PubMed  Google Scholar 

Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77:1865–79. https://doi.org/10.1007/s40265-017-0829-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choy EH, de Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16:335–45. https://doi.org/10.1038/s41584-020-0419-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021;27:52–66. https://doi.org/10.1016/j.pulmoe.2020.07.003.

Article  CAS  PubMed  Google Scholar 

Hasanin A, Mostafa M. Tocilizumab in patients with COVID-19: which patient, time, and dose? J Anesth. 2021;35:896–902. https://doi.org/10.1007/s00540-021-02974-0.

Article  PubMed  PubMed Central  Google Scholar 

Kow CS, Hasan SS. Interleukin-6 blockade with tocilizumab in COVID-19: does it live up to its hype? Pulmonology. 2021;27:86–7. https://doi.org/10.1016/j.pulmoe.2020.10.004.

Article  CAS  PubMed  Google Scholar 

Klopfenstein T, Gendrin V, Kadiane-Oussou NJ, Conrozier T, Zayet S. Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022;32:e2239. https://doi.org/10.1002/rmv.2239.

Article  CAS  PubMed  Google Scholar 

Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022;28:222–38. https://doi.org/10.1016/j.cmi.2021.11.007.

Article  CAS  PubMed  Google Scholar 

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Siemieniuk RA, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. https://doi.org/10.1136/bmj.m3379.

Article  PubMed  Google Scholar 

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64. https://doi.org/10.1182/blood-2008-05-155846.

Article  CAS  PubMed  Google Scholar 

Cremer S, Jakob C, Berkowitsch A, Borgmann S, Pilgram L, Tometten L, et al. Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clin Res Cardiol. 2021;110:1029–40. https://doi.org/10.1007/s00392-020-01769-9.

Article  CAS  PubMed  Google Scholar 

Freise NF, Gliga S, Fischer JC, Lübke N, Lutterbeck M, Schöler M, et al. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort. Sci Rep. 2022;12:19035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384:1491–502. https://doi.org/10.1056/NEJMoa2100433.

Article  PubMed  Google Scholar 

Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9:511–21. https://doi.org/10.1016/S2213-2600(21)00081-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24–31. https://doi.org/10.1001/jamainternmed.2020.6615.

Article  CAS  PubMed  Google Scholar 

Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020;383:2333–44. https://doi.org/10.1056/NEJMoa2028836.

Article  CAS  PubMed  Google Scholar 

Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30:1–9. https://doi.org/10.1002/rmv.2141.

Article  CAS  PubMed  Google Scholar 

Verboogen DRJ, Revelo NH, Ter Beest M, van den Bogaart G. Interleukin-6 secretion is limited by self-signaling in endosomes. J Mol Cell Biol. 2019;11:144–57. https://doi.org/10.1093/jmcb/mjy038.

Article  CAS  PubMed  Google Scholar 

Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2021;147:72–80. https://doi.org/10.1016/j.jaci.2020.09.018.

Article  CAS  PubMed  Google Scholar 

Mandel M, Harari G, Gurevich M, Achiron A. Cytokine prediction of mortality in COVID19 patients. Cytokine. 2020;134:155190. https://doi.org/10.1016/j.cyto.2020.155190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lakatos B, Szabo BG, Bobek I, Gopcsa L, Beko G, Kiss-Dala N, et al. Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab. Acta Microbiol Immunol Hung. 2021. https://doi.org/10.1556/030.2021.01526.

Article